Personalized HLA-aware TCR measure predicts the risk of symptomatic SARS-CoV-2 infection following booster vaccination

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

HLA-driven heterogeneity and limitations of live T cell functional assays routinely thwart assessment of cell-mediated immunity in vaccination trials. To address this, we developed a T-cell receptor (TCR)-based measure of immunogen recognition and evaluated it in COV-BOOST, a third-dose COVID-19 vaccine trial, during the Delta and Omicron waves (2021-2022, United Kingdom). We estimated HLA-aware Spike-reactive T cell (HA-T S ) breadth from participant HLA genotypes, TCRβ repertoires, and a novel SARS-CoV-2 Spike HLA-linked reference catalog. Higher post-boost HA-T S breadth was associated with lower symptomatic infection risk (HR 0.58, 95% CI 0.39–0.86). This association persisted after adjustment for neutralizing antibody titers and IFN-γ responses. Examination of HA-T S across prior studies showed that it reflects participant genotype, exposure intensity, and time from exposure to sampling. These findings highlight the possibility that estimates of antigen-specific T cell repertoire breadth could serve as a correlate of protection to accelerate vaccine development.

Article activity feed